Hepar Chimie S.a.

Other

Crinos Industria Farmacobiologica S.p.a.

Mediolanum Farmaceutici, S.r.l.

Laboraton Derivati Organici, S.p.a.

Gianfranco Fedeli

Fernando Fussi

Giuseppe Diamantini

Giuseppe Prino

Marisa Mantovani

Wiktor Djaczenko

Luigi De Ambrosi

Marisa Maontovani

Maria Strumillo

Depolymerization of stabilized solutions of highly polymerized and nicked polydeoxyribonucleotides, as obtained through stabilizing aggregation of raw nucleic acids, the depolymerization being carried out by heating at controlled temperature and being controlled as a function of the variation of the reversible hyperchromicity, followed by the removal of the hydrogen bonds in the double stranded filaments and by thermal stabilization of the single stranded filaments, polydeoxyribonucleotide is obtained. The polydeoxyribonucleotide has the following formula of random sequence:

Process for obtaining chemically defined and reproducible

By carrying out the depolymerization of stabilized solutions of highly polymerized and nicked polydeoxyribonucleotides, as obtained through stabilizing aggregation of raw nucleic acids, the depolymerization being carried out by heating at controlled temperature and being controlled as a function of the variation of the reversible hyperchromicity, followed by the removal of the hydrogen bonds in the double stranded filaments and by thermal stabilization of the single stranded filaments, the polydeoxyribonucleotide, known as Defibrotide is obtained. Defibrotide has the following formula of random sequence:

Tetrachlorobenzoic acid derivative having the formula: ##STR1## (2-trichloroacetoxy-3,4,5,6-tetrachlorobenzoic acid), chemotherapeutically active against cutaneous and subcutaneous benign neoformations, process for its preparations and compositions containing the same.

2-Trichloroacetoxy-3,4,5,6-tetrachlorobenzoic acid and compositions

A oligo-heteropolysaccharide is disclosed which is very active against thrombotic syndromes and is prepared starting from depolymerized heparin fractions wherein the active groups, more particularly the sulfuric groups have been reconstituted by reacting a heparin fraction with a mol wt from 2,000 to 5,000 with the sulfotrioxide of a nitrogeneous organic base such as pyridine and trimethylamine. The method of preparation is also disclosed.

Oligo-heteropolysaccharides having a heparin-like activity method for

An arterial polysaccharide complex of anionic character consisting of hexosamine glycanmonosulphates (FAPA) derived from the aorta of young mammals and a process for its preparation.

Arterial polysaccharide complex, a method for its preparation and

Natural heteropolysaccharide, specifically hexuronyl hexosaminoglycane sulfate and, a process to obtain it, which substantially provides for the following steps:

Natural hexuronyl hexosaminoglycane sulfate, method for the preparation

Hexuronyl hexosaminoglycane sulfate and related therapeutical uses

Protease inhibitor is extracted from fresh or frozen organs of slaughtered animals by an enzymolysis operation which excludes any possibility of interference by azymic autolysis, the enzymolysis being stopped after a time not exceeding 4 hours, whereafter a lysate aqueous solution is obtained by filtration and a quaternary ammonium base is added to the lysate solution to precipitate insolubles, the filtrate being the fraction which contains the expected protease inhibitor.

Extracting protease-inhibitor from animal tissue containing same

From the residual liquors of the extraction of active principles, particularly heparin, from animal organs, a fraction of natural polyanions is obtained having, besides clearing and anticoagulant activity, also antiphlogistic and anti-inflammatory activity as well as stimulating activity on the reticuloendothelial system, whereby it is useful in the treatment of atherosclerosis and related diseases. The process for obtaining these natural polyanions is also disclosed.

Growing community of inventors

Milan, Italy

Gianfranco Fedeli